The U.S. Food and Drug Administration has approved UCB’s Bimzelx (bimekizumab-bkzx) for the treatment of adults with moderate-to-severe hidradenitis suppurativa.
This article was originally published on MedicalXpress.com
FDA approves Bimzelx for hidradenitis suppurativa
You may also be interested in:
The Latest
Why stress-related illness is so hard to diagnose, and how a patient-centred playful approach can help
For at least three decades, researchers have gathered evidence that chronic stress puts pressure on the body to constantly adjust itself to restore physiological stability. This process is known as allostatic load and it creates a cascade […]
The Latest
Why you should stop buying vitamins and get more sleep instead
Almost half of all Canadians regularly take at least one nutritional supplement such as vitamins, minerals, fibre supplements, antacids and fish oils. Many of these individuals are healthy and hoping to improve general well-being or prevent chronic […]
The Latest
Avoiding Common Relationship Mistakes for a Happier Love Life
Fostering a rewarding and fulfilling relationship is no easy task. You and your partner are only human, and, as the saying goes, you are going to make mistakes. However, learning the common relationship mistakes and […]
Read More:
-
Learning French while also developing language skills in one’s mother tongue is no easy task. As a result, allophone children often face learning and communication [...]
-
People who develop multiple sclerosis (MS) as children and grow up in less advantaged neighborhoods may have a larger volume of inflammation and brain tissue [...]
-
Children of mothers who took certain antiseizure medications while pregnant do not have worse neurodevelopmental outcomes at age 6, according to a long-running study. The [...]
